Apnimed is developing oral therapies that target the neuromuscular dysfunction associated with obstructive sleep apnea (OSA) to improve oxygenation and enhance sleep quality. Their investigational therapy, AD109, aims to provide a simpler treatment option for individuals who are currently untreated or undertreated for OSA.
Funding
$207.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Obstructive sleep apnea (OSA) is often untreated or undertreated, leading to poor oxygenation and disrupted sleep due to neuromuscular dysfunction. Current treatments can be complex and poorly accepted by individuals with OSA.
Solution
Apnimed is developing novel oral therapies, including their investigational therapy AD109, designed to address the underlying neuromuscular dysfunction associated with OSA. These therapies aim to simplify treatment, improve oxygenation, and enhance sleep quality for individuals with sleep-related breathing disorders. By targeting the neuromuscular mechanisms, Apnimed seeks to provide a more broadly acceptable and effective treatment option for those who are currently untreated or undertreated for OSA.
Target Audience
The primary target audience includes individuals with obstructive sleep apnea (OSA) who are currently untreated or undertreated, as well as healthcare providers seeking simpler and more effective treatment options.
Features
- AD109: Investigational oral therapy targeting neuromuscular dysfunction in OSA.
- Designed to improve oxygenation and enhance sleep quality.
- Aims to simplify OSA treatment and increase patient acceptance.
- Focus on addressing the underlying causes of sleep-related breathing diseases.